MAPK3 and breast carcinoma: An anti-apoptotic mechanism also mediates the resistance to paclitaxel in estrogen-sensitive breast cancer cells, where ERK1/2 promotes the transcriptional up-regulation of survivins by recruiting p53 on the survivins promoter [96].